Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Scholar Rock Holding Corporation - Common Stock
(NQ:
SRRK
)
37.07
-0.56 (-1.49%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Scholar Rock Holding Corporation - Common Stock
< Previous
1
2
3
4
Next >
What's going on in today's after hours session
February 14, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
January 28, 2025
Via
Benzinga
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
January 15, 2025
Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.
Via
Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Exposures
Artificial Intelligence
Political
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
October 25, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 04, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
December 01, 2024
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 25, 2024
Via
Benzinga
How Is The Market Feeling About Scholar Rock Holding?
October 07, 2024
Via
Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
November 25, 2024
Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.
Via
Benzinga
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
November 25, 2024
Via
Benzinga
Here's Why Everybody's Talking About Scholar Rock Right Now
October 09, 2024
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
Via
The Motley Fool
Nasdaq To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday
October 08, 2024
Via
Benzinga
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
October 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 07, 2024
Via
Benzinga
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
October 07, 2024
Via
Benzinga
Exposures
Fossil Fuels
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...
Via
Benzinga
Exposures
Product Safety
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
October 07, 2024
Via
Benzinga
US Stocks Open Lower; Dow Tumbles Over 150 Points
October 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
October 07, 2024
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 07, 2024
Via
Benzinga
Constellation Energy, Nike, Sinclair And Other Big Stocks Moving Higher On Friday
September 20, 2024
Via
Benzinga
SRRK Stock Earnings: Scholar Rock Holding Beats EPS for Q2 2024
August 08, 2024
SRRK stock results show that Scholar Rock Holding beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
June 03, 2024
Via
Benzinga
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024
May 07, 2024
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
April 24, 2024
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Via
InvestorPlace
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
March 28, 2024
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to
Via
Benzinga
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023
March 19, 2024
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.